2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024 PMID: 39014969, DOI: 10.1111/bju.16403.Peer-Reviewed Original ResearchPapillary renal cell carcinomaPositive predictive valueRenal cell carcinomaLocal pathology reviewCentral reviewPathology reviewCell carcinomaAdvanced papillary renal cell carcinomaMetastatic papillary renal cell carcinomaPapillary renal cell carcinoma subtypesPatients treated with targeted therapyExpert genitourinary pathologistsPathological concordance rateLocal reviewGenitourinary pathologistsClinical benefitCabozantinibClinical significanceClinical valueSubtype assignmentConcordance rateType 1CarcinomaPatientsPredictive valueEfficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Kamat A, Bivalacqua T, Montgomery J, Lerner S, Busby J, Poch M, Crispen P, Steinberg G, Schuckman A, Downs T, Mashni J, Lane B, Guzzo T, Bratslavsky G, Karsh L, Woods M, Brown G, Canter D, Luchey A, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Sankin A, O’Donnell M, Sawutz D, Philipson R, Parker N, Yla-Herttuala S, Rehm D, Jakobsen J, Juul K, Dinney C. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. Journal Of Urology 2024, 212: 74-86. PMID: 38704840, DOI: 10.1097/ju.0000000000004020.Peer-Reviewed Original ResearchConceptsNonmuscle-invasive bladder cancerPhase 3 trialBladder cancerFollow-upAdenoviral vector-based gene therapyProgression to muscle-invasive diseaseOpen-label phase 3 trialVector-based gene therapyCystectomy-free survivalMuscle-invasive diseaseMedian follow-upCarcinoma in situBladder preservationNadofaragene firadenovecOverall survivalGene therapyCytological assessmentTa/T1PatientsUS sitesCohortReceiving treatmentMonthsCancerHGRFInfigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
Pal S, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama B, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin S, Loriot Y, Sridhar S, Sonpavde G, Fleming M, Lerner S, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. European Urology 2024 PMID: 38580518, DOI: 10.1016/j.eururo.2024.03.023.Peer-Reviewed Original Research
2023
Functional Follow-Up After Cystectomy and Urinary Diversion: A Narrative Review
Kaufmann E, Black P, Catto J, Djaladat H, Ghodoussipour S, Hamilton-Reeves J, Jensen B, Kassouf W, Lauridsen S, Lerner S, Llorente C, Loftus K, Lucca I, Martini A, Preston M, Psutka S, Sfakianos J, Shah J, Wettstein M, Williams S, Daneshmand S, Fankhauser C. Functional Follow-Up After Cystectomy and Urinary Diversion: A Narrative Review. JU Open Plus 2023, 1 DOI: 10.1097/ju9.0000000000000071.Peer-Reviewed Original ResearchUrinary diversionFunctional complicationsCurrent guideline recommendationsQuality of lifeInstitutional followGuideline recommendationsSexual functionFunctional resultsMetabolic disturbancesNarrative reviewCystectomyLiterature searchLimited evidenceFollowRoutine implementationSurveillance proceduresComplicationsPatientsDifferent recommendationsFunctional followDiversionReviewRecommendationsImpairment